FDA Clears Controlled Contrast Delivery Method for Ultrasound Imaging of Fallopian Tubes
Facilitating natural contrast delivery through an intrauterine catheter, FemChec can be utilized for ultrasound assessment of fallopian tubes and may provide diagnostic confirmation for an emerging non-surgical option for permanent birth control.
The Food and Drug Administration (FDA) has granted 510(k) clearance for FemChec®, a modality that generates natural contrast for use in ultrasound imaging of fallopian tubes. This imaging may potentially be utilized to confirm the success of FemBloc®, a non-surgical approach to permanent birth control that is currently being evaluated in a clinical trial.
Using an intrauterine catheter, clinicians can employ FemChec to provide a continuous contrast media stream of alternating saline and air to enhance ultrasound visualization of the fallopian tubes with or without the uterine cavity, according to Femasys, the developer of FemChec and FemBloc.
The recently FDA-cleared FemChec®, which generates natural contrast for use in ultrasound imaging of fallopian tubes, may potentially play a key diagnostic role in confirming the results of a non-surgical approach to permanent birth control (FemBloc®) that is currently being evaluated in a clinical trial. (Photo courtesy of Adobe Stock.)
The company said the combination of natural contrast and ultrasound may provide a viable alternative to traditional X-ray and corresponding radiation exposure for evaluating fallopian tubes.
“FemChec is an essential part of our suite of women’s health products as it fortifies our position to provide safe and technologically advanced diagnostic and therapeutic solutions addressing women’s health care needs,” noted Kathy-Lee Sepsick, the chief executive officer and founder of Femasys.
New AI-Enabled Portable Ultrasound May Facilitate 50 Percent Reduction in Cardiac Imaging Scan Time
March 28th 2025Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which will be unveiled at the American College of Cardiology (ACC) conference.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
